NEW YORK (TheStreet) -- Shares of ZS Pharma Inc (ZSPH) were higher by 3.61% to $58.54 in mid-morning trading Friday, after analysts at JPMorgan Chase raised their price target on shares of the biotech company to $75 from $57 earlier today.

The firm maintained its "overweight" rating on the name, but hiked its price target following the stock's 45% gain this month saying the stock is "no longer in stealth mode."

JPMorgan analysts believe that treating hyperkalemia, or high-blood potassium levels, represents a multi-billion dollar opportunity just in the U.S. 

"Given the increased investor dialogue, imminent NDA filing, and recent publications, we thought this would be a good time to address the questions we get on the relative competitive positioning of ZS-9 for the treatment of hyperkalemia (high blood potassium)," the firm wrote in a note this morning.

Coppell, Texas-based ZS Pharma is a biopharmaceutical company focused on the development and commercialization of highly selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.

The Company's product candidate, sodium zirconium cyclosilicate completed Phase III development for the treatment of hyperkalemia, a life-threatening condition.

ZSPH ChartZSPH data by YCharts

If you liked this article you might like

AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment

AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment

2 Speculative Biotech Stocks for 2016

2 Speculative Biotech Stocks for 2016

The Nominees for Best Biopharma CEO of 2015 Are...

The Nominees for Best Biopharma CEO of 2015 Are...

Why Relypsa Is a New 'Best Idea'

Why Relypsa Is a New 'Best Idea'

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio

Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio